Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Fortress Biotech (FBIO) over the last 13 years, with Q3 2025 value amounting to $45.2 million.

  • Fortress Biotech's Accounts Payables fell 2996.64% to $45.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.2 million, marking a year-over-year decrease of 2996.64%. This contributed to the annual value of $65.5 million for FY2024, which is 1095.81% down from last year.
  • Per Fortress Biotech's latest filing, its Accounts Payables stood at $45.2 million for Q3 2025, which was down 2996.64% from $48.6 million recorded in Q2 2025.
  • Fortress Biotech's Accounts Payables' 5-year high stood at $105.4 million during Q1 2023, with a 5-year trough of $39.2 million in Q1 2021.
  • Over the past 5 years, Fortress Biotech's median Accounts Payables value was $76.4 million (recorded in 2024), while the average stood at $76.0 million.
  • Its Accounts Payables has fluctuated over the past 5 years, first skyrocketed by 15460.94% in 2021, then plummeted by 3049.66% in 2024.
  • Fortress Biotech's Accounts Payables (Quarter) stood at $90.7 million in 2021, then rose by 7.49% to $97.4 million in 2022, then fell by 24.51% to $73.6 million in 2023, then dropped by 10.96% to $65.5 million in 2024, then crashed by 31.04% to $45.2 million in 2025.
  • Its last three reported values are $45.2 million in Q3 2025, $48.6 million for Q2 2025, and $66.3 million during Q1 2025.